BCG vaccination and risk of XXXX .

@entity1 @entity402 @entity56
CONTEXT: It has been suggested that BCG vaccination may protect against development of @entity56 , particularly when given just after birth. BCG vaccination was given routinely to all @entity1 in Greenland until 1990, when it was withdrawn from the vaccination program. Whether this resulted in an increased prevalence of @entity402 in @entity1 born after the stop of BCG vaccination is unknown. OBJECTIVE: To determine whether BCG vaccination and age at BCG vaccination are associated with development of @entity402 . DESIGN, SETTING, AND @entity1 : Cross-sectional study among schoolchildren aged 8 to 16 years in 4 towns on the northwest coast of Greenland. @entity1 had a blood sample drawn and information on BCG vaccination was obtained during 2 periods, November 1998 and November 2001. A total of 1686 @entity1 (79% of available @entity1 ) participated, 1575 of whom had complete information on vaccination status. Atopy was defined as a positive test result in an assay that tests for IgE specific against the most common inhalant allergens in serum. MAIN OUTCOME MEASURES: Odds ratio (OR) of @entity402 in BCG-vaccinated compared with unvaccinated @entity1 and OR according to age at vaccination. RESULTS: The risk of @entity402 was the same in BCG-vaccinated compared with unvaccinated @entity1 after adjustment for confounders (OR, 1.03; 95% confidence interval, 0.72-1.48). The risk of @entity402 in BCG-vaccinated @entity1 was not associated with age at vaccination (P =.17). CONCLUSIONS: BCG vaccination administered to @entity1 is not associated with reduced risk of development of @entity402 .
